The aim of this study was to analyze the correlation between the dental plaque indices measured different imaging systems and conventional clinical indices that assess dental plaque. From among the patients who visited Marmara University, Faculty of Dentistry 30 adults between the age of 18-30, who had under 3 DMFT scores, were selected for full-mouth imaging. Digital dental photography, digital scanning system and fluorecam methods were used for taking intraoral images. The Turesky Modified Quigley Hein Plaque Index (TMQHPI) was scored both by the clinical examination method and on the images taken. The correlations between the clinical examinaton, digital photography, digital scanning system and fluorecam scores were analyzed. Maxillary and mandibulary anterior teeth's buccal surfaces were scored to TMQHPI after using disclosing agent.

开始日期2021-05-17

申办/合作机构

Marmara University

NCT04360044 / Completed临床2期IIT

Efficacy of Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial

This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.

开始日期2020-11-20

申办/合作机构

University of California San Diego

[+1]

NCT01695850 / Completed临床2期IIT

Chinese Herbal Medicine (MaZhiRenWan) for Functional Constipation: a Prospective, Double-blinded, Double-dummy, Randomized Controlled Study

The objective of this study is to evaluate the efficacy and safety of a Chinese herbal proprietary medicine, MaZiRenWan (MZRW), by comparing with stimulant laxative western medicine (WM), senna, and placebo for patients with functional constipation (FC) in excessive TCM syndrome.

开始日期2013-06-01

申办/合作机构

香港浸会大学

[+1]

100 项与麻子仁丸相关的临床结果

登录后查看更多信息

100 项与麻子仁丸相关的转化医学

登录后查看更多信息

100 项与麻子仁丸相关的专利（医药）

登录后查看更多信息

255

项与麻子仁丸相关的文献（医药）

2024-02-01·Journal of texture studies

Sensory properties of thickened tomato soup enhanced with different sources of protein (whey, soy, hemp, and pea)

Article

作者: McSweeney, Matthew B ; Gorman, Mackenzie ; Dabas, Tanvi ; Moss, Rachael ; Amyoony, Jamal

Abstract:

Thickened soup formulations were created with different proteins (hemp, soy, pea, and whey) to improve protein and fluid intake. The formulations consisted of a control soup, and soups with 6% whey protein, 6% hemp protein, 6% pea protein, and 6% soy protein by volume. The suitability of the samples for those living with dysphagia was evaluated using the international dysphagia diet standardization initiative (IDDSI) spoon tilt test and a sensory trial (51 older adults and 51 younger adults). The sensory trial used nine‐point hedonic scales and check‐all‐that‐apply to evaluate the different formulations. The sample with the whey addition was not significantly different than the control in terms of liking of flavor and texture, but it decreased the participants' overall liking. The hemp, pea, and soy decreased overall liking as well as liking of flavor and texture. They were associated with off‐flavors, aftertaste, and astringency. The responses from the older and younger adults were compared and significant differences were found in their liking of the texture, with the older adults finding the formulations' texture significantly more acceptable. Overall, the study identified that hemp, pea, and soy did not create acceptable thickened soup formulations and the hemp and pea formulations did not achieve a consistency level that is acceptable for those living with dysphagia.

2024-02-01·Fundamental & clinical pharmacology

Can cannabidiol have an analgesic effect?

Review

作者: Kurzepa, Jacek ; Kulesza, Bartłomiej ; Mazurek, Marek

Abstract:

Background:

Cannabis, more commonly known as marijuana or hemp, has been used for centuries to treat various conditions. Cannabis contains two main components cannabidiol (CBD) and tetrahydrocannabinol (THC). CBD, unlike THC, is devoid of psychoactive effects and is well tolerated by the human body but has no direct effect on the receptors of the endocannabid system, despite the lack of action on the receptors of the endocannabid system.

Objectives and methods:

We have prepared a literature review based on the latest available literature regarding the analgesic effects of CBD. CBD has a wide range of effects on the human body. In this study, we will present the potential mechanisms responsible for the analgesic effect of CBD. To the best of our knowledge, this is the first review to explore the analgesic mechanisms of CBD.

Results and conclusion:

The analgesic effect of CBD is complex and still being researched. CBD models the perception of pain by acting on G protein‐coupled receptors. Another group of receptors that CBD acts on are serotonergic receptors. The effect of CBD on an enzyme of potential importance in the production of inflammatory factors such as cyclooxygenases and lipoxygenases has also been confirmed. The presented potential mechanisms of CBD's analgesic effect are currently being extensively studied.

2024-02-01·The International journal on drug policy

Reported exposures to derived cannabis products in California before and after the 2018 federal reclassification of hemp

Article

作者: Apollonio, Dorie E ; Ho, Raymond ; Chami, Raeiti Fouladi ; Madan, Kunal ; Schmidt, Samantha ; Lewis, Justin C

BACKGROUND:

As of June 2023, a majority of states had legalized the sale of cannabis, which past research has found to be associated with increased exposures. In 2018, a change in federal policy increased access to cannabidiol (CBD) and derived psychoactive cannabis products, but there has been limited study of reported exposures following this change.

METHODS:

This observational retrospective study analyzed exposures involving synthetic cannabinoid receptor agonists (SCRAs) and derived cannabis products, including CBD, reported to the California Poison Control System (CPCS) from 2010 to 2022. We focused primarily on potential shifts in reported exposures before and after the implementation of the 2018 Farm Bill, which removed products derived from hemp from the Controlled Substances Act. We reviewed and hand-coded individual call records to assess reported exposures over time and their characteristics, and conducted interrupted time series analysis to assess whether exposure counts changed after policy interventions.

RESULTS:

Reported CBD exposures significantly increased following the federal reclassification of hemp products. Exposure reports were most common among young children and for edibles. Exposure reports provided limited information about derived psychoactive cannabis products.

CONCLUSIONS:

Our findings suggest a need for improved data collection regarding derived psychoactive cannabis products, as well as potential public health value in modifying packaging regulations and in providing additional guidance to parents to help prevent CBD exposures.

项与麻子仁丸相关的新闻（医药）

2024-06-15

·米内网

【米交汇前瞻】中医药复兴迎战略机遇期！如何推进产业链卓越创新？

精彩内容在中医药理论创新指导下，部分中成药经过市场营销后已成为明星产品，如苏黄止咳胶囊、麝香保心丸、金水宝片等。中医药事业正处于复兴的战略机遇期，但仍亟待攻坚克难。6月27日上午，米思会分会——【米交汇】中医药创新生态合作论坛将围绕当前亟待通过研发链合作创新提高研发创新力度、聚焦卓越创新等行业痛点，通过一批行业大咖的主旨演讲及圆桌论坛碰撞，探索重磅中药创新药的发展模式。中医药事业正处于复兴的战略机遇期 1、中医药理论创新已经培育一批重磅中药创新药米内网中国公立医疗机构终端内服中成药TOP20产品显示，相当多的口服中成药，比如苏黄止咳胶囊、麝香保心丸、金水宝片等，即使在疫情、医保管理加强的情况下，市场依然有不错的增长，且相当部分口服中成药在中国公立医疗机构终端的年市场规模都超过20亿元。 2023年中国公立医疗机构终端内服中成药TOP20产品来源：米内网格局数据库在对主要产品的成功因素进行分析中，发现大多数TOP20中成药源自经典名方化裁，或者源自长期使用的临床经验方，在经过产业转化、临床试验验证后，获批上市并进入相关诊治指南及医保目录，经过市场营销后成为市场明星产品。 2、中医药理论创新厚积薄发作为重磅创新中药源头的中医药理论创新这几十年在国家各项政策推动下正逐渐厚积薄发，国家中医医疗体制机制不断完善，各大流派百家争鸣，国医大师群体不断壮大，出现如《脉络学说》等系统理论创新著作，各疾病理论涌现一批创新理解，被《Science Advances》收录的中医药论文数量快速提高。 3、产业相关政策对中医药温柔以待国家宏观层面对中医药事业的支持正逐渐转化为监管及医保方面的支持，注册管理方面充分尊重中医药科学规律，2023年出台了《中药注册管理专门规定》，符合条件的可不开展非临床有效性研究、可简化药毒性试验、可不开展二期临床试验、可用真实世界研究作为上市依据、可不提供包材研究；医保不管在集采、国谈还是在医保支付管理方面，对中医药整体相对温柔。复兴的中医药事业亟待攻坚克难 1、中药创新亟待大力提高研发创新力度总体而言，与小分子化学药、大分子生物制剂相比，中药创新药获批上市的比例依然较低，这也意味着总体而言对临床贡献相对偏低。这种局面的改变既需要前端中医药理论创新进一步提高，也需要加强成果转化力度，以及各企业研发创新管线布局力度进一步提高。来源：《2023年度药品审评报告》 2、中药创新药期待临床价值的卓越创新临床价值的重要表现是产品被相关诊治指南推荐，尤其是被国际、国内主流临床诊治指南推荐。虽然当前已经有相当部分中药大品种被相关中西医临床诊治指南推荐，但被列入西医主流临床诊治指南，甚至国际临床诊治指南的凤毛麟角，这也亟待中药创新药更注重临床价值创新力度。【米交汇】中医药创新生态合作论坛聚焦产业链卓越创新突围在即将展开的2024米思会上，中国中医科学院中药研究所资深研究员、北京盈科瑞创新医药股份有限公司张保献董事长将主持6月27日上午【米交汇】中医药创新生态合作论坛，论坛将围绕当前亟待通过研发链合作创新提高研发创新力度、聚焦卓越创新等行业痛点，通过一批行业大咖的主旨演讲及圆桌论坛碰撞，探索重磅中药创新药的发展模式。在主旨演讲环节，中国医学科学院药用植物研究所孙晓波原所长将从宏观角度与来宾分享《创新驱动助力中药产业高质发展》；香港浸会大学中医药研发中心科学顾问、前FDA植物药资深评审员窦金辉博士将通过国际化视角，从临床价值角度，为大家带来《借古人经典和现代化科技推动中药国际化》；粤港澳大湾区药品与医疗器械真实世界研究院蒋杰院长将从港澳先行经验角度，与大家分享《港澳中药外用制剂简化注册及案例分享》；香港浸会大学襄理副校长、香港中医院卞兆祥院长将通过案例形式分享《以麻子仁丸为例探究中药复方转化医学研究思路》；北京盈科瑞创新医药股份有限公司李艳英科研总裁将通过新药研发关键共性技术角度，与来宾探讨《经典名方研究关键技术探讨及获批案例分享》...... 在《如何通过产学研合作培育重磅中药创新药》环节，米内网创新力中心研究总监谢立峰将与上药集团中药研究所刘雳所长、天士力医药集团副总经理、研究院周水平执行院长、北京盈科瑞创新医药股份有限公司张宏武总裁、康臣药业集团李政海副总裁，扬子江药业集团江苏龙凤堂中药研究院侯金才院长共同碰撞《如何用慧眼甄别具有重磅潜质的待转化项目》、《如何以重磅中药为导向高效推进各环节开发》、《通过产业生态合作开发重磅中药需要避开哪些坑》...... 培育具有卓越价值的中药大产品，我们正在路上，欢迎大家参加2024米思会，并参加6月27日上午的由米内网主办，由北京盈科瑞协办的【米交汇】加强产业链融合，助力中医药科技成果转化----中医药创新生态合作论坛！议程持续更新中，请以大会现场为准附：韧进·启新局！2024米思会最新议程本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

2024-02-02

·PRNewswire

Study on the safety of Elixinol Hemp Extract is published in Journal of Toxicology

SYDNEY, Feb. 2, 2024 /PRNewswire/ -- Elixinol Wellness Limited (ASX: EXL) continues to be a pioneer in the global hemp industry, with the release of a new paper into the safety of Elixinol Hemp Extract in leading scientific publication, Journal of Toxicology. The paper, entitled "Safety of Elixinol Hemp Extract: In VitroGenetic Toxicity and Subchronic Toxicity in Rat", reports on safety studies of Elixinol Hemp Extract in rats and concludes that the Extract is safe to use and does not have any adverse effects at the highest dose tested. The paper also suggests that the Elixinol Hemp Extract may have some benefits for human health, with additional studies needed to confirm this. Elixinol Group CEO and Managing Director, Ron Dufficy, said: "The positive safety results, now published in a well-respected scientific journal, stand Elixinol Hemp Extract and Elixinol more broadly in good stead for the future of our hemp products and offerings." Elixinol Hemp Extract contains a blend of hemp extract, cannabidiol (CBD) isolate, and copaiba. CBD is a compound that comes from the cannabis plant and copaiba is a resin that comes from a tropical tree and has anti-inflammatory properties. The paper details two studies that tested the effects of the Elixinol Hemp Extract on rats. The first study was a short-term 15-day study and the second was a long-term 90-day study. The study found that the Extract did not cause any harmful effects on the rats. It did note some changes in the rats' liver cells and liver weight, however these changes were not serious and did not affect the liver function. The changes also reversed once the Extract was stopped. The paper concludes, "The results from the present studies indicate that Elixinol Hemp Extract is well tolerated in male and female Sprague–Dawley rats and this information contributes to the growing amount of safety information available for hemp extracts and specifically highlights the safety profile of Elixinol Hemp Extract." The full paper can be accessed via this link: SOURCE Elixinol Wellness Limited

2023-11-15

·PRNewswire

Premium Jane One of First USA Companies to Offer THCA Hemp Flower Online

SCOTTSDALE, Ariz., Nov. 15, 2023 /PRNewswire/ -- Premium Jane, a reputable USA-based company and a longstanding trusted name in the CBD industry, is set to redefine the landscape of the hemp industry with the groundbreaking release of a new line of THCA hemp-derived flower. Amidst the growing interest in 'alternative' wellness products like delta-8 THC and Delta-9, Premium Jane leverages years of trust and expertise to bring forth this exciting - and fairly revolutionary - product. "Premium Jane has been one of the most trusted names in the CBD industry for years," says Premium Jane owner Jeff Yauck. "With this new THCA hemp-derived flower line, we are taking a bold step into exciting new territory, providing consumers with a unique way to experience the magic of Hemp." Research suggests THCA may also possess a variety of benefits, making it a promising addition to the wellness market. Yauck emphasizes the importance of offering consumers diverse options for incorporating hemp into their daily routines. "At Premium Jane, we've always believed in empowering individuals to explore natural solutions to well-being. This new THCA hemp-derived flower is a testament to our commitment to providing innovative products that cater to the evolving needs and demands of people across the USA." The new Premium Jane THCA hemp-derived flower line is grown in the USA and lab-tested to ensure purity and verify levels of THCA and other cannabinoids. Each batch undergoes rigorous testing to meet Premium Jane's standards for excellence and safety. "We understand the responsibility that comes with providing hemp-derived products, and we take every step of the process seriously. Every step of production is geared towards offering a product that exceeds expectations," says Yauck. "Premium Jane THCA flower is a result of meticulous cultivation and years of dedication to delivering the most exciting and powerful products on the market." Premium Jane anticipates high demand for the new product line, and is encouraging customers to act fast before the initial batches sell out. For more information or to browse the lineup online, visit . Contact: Premium Jane [email protected] SOURCE Premium Jane

100 项与麻子仁丸相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
便秘	日本	Ohsugi Pharmaceutical Co., Ltd.	1986-08-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00299975 (CTgov)	临床2期	功能性便秘	97	MaZiRenWan (MZRW) (Low Dose Group)	膚築醖網觸鹹選積餘鑰(願遞觸獵遞簾壓顧餘廠) = 構願艱簾齋壓網夢製構築蓋艱醖衊鹽廠蓋餘繭 (壓壓築範蓋築衊築製鏇, 鹽夢淵積築衊鬱夢選膚 ~ 築齋壓築鹹積製鹹製壓) 更多	-	2011-12-16
				MaZiRenWan (MZRW) (Median Dose Group)	膚築醖網觸鹹選積餘鑰(願遞觸獵遞簾壓顧餘廠) = 願選範壓鹽積鏇淵遞製築蓋艱醖衊鹽廠蓋餘繭 (壓壓築範蓋築衊築製鏇, 窪衊鬱遞鑰憲鬱襯廠遞 ~ 淵構糧鑰築鑰鑰齋蓋願) 更多